LDS/Medical Tests/MLH1 Hypermethylation (Promoter Methylation) Analysis, Tissue

MLH1 Hypermethylation (Promoter Methylation) Analysis, Tissue

The MLH1 gene is located in the short (p) arm of chromosome 3 at position 22.2 and encodes MutL homolog1 protein that plays an essential role in DNA repair. It is a human homolog of the E. coli DNA mismatch repair gene, mutL, which mediates protein-protein interactions during mismatch recognition, strand discrimination, and strand removal. The MLH1 gene is a member of a set of genes known as the mismatch repair (MMR) genes. The repairs are made by removing sections of a DNA that contain errors and replacing the sections with a correct DNA sequence.

Defects in MLH1 are associated hereditary nonpolyposis colon cancer (HNPCC) or Lynch syndrome. Although Lynch syndrome may be caused by mutations in one of several MMR genes, about 50% of Lynch syndrome patients have a germline mutation in one MLH1 allele. Cancer occurs when the second MLH1 gene is inactivated by somatic mutation, loss of heterozygosity or epigenetic silencing secondary to promotor hypermethylation. Lack of functional MLH1 results in an increased genomic instability particularly in areas of repetitive genetic sequences termed “microsatellites”. The expansion or contraction of these microsatellite regions in tumor as compared to normal tissue is termed ‘microsatellite instability’ and is a characteristic finding in Lynch syndrome as well as in 10-15% of sporadic colon cancers. Individuals with Lynch syndrome also have an increased incidence of cancers of the endometrium, ovary, stomach, small intestine, hepatobiliary system, renal pelvis, ureter and brain.

  • MLH1 promoter methylation analysis is useful to distinguish sporadic from inherited colorectal and endometrial cancers in tumors that are MLH1-deficient by IHC staining and/or have high levels of microsatellite instability (MSI-H)
  • Methylation Analysis of MLH1 improves the selection of patients for genetic testing in Lynch Syndrome
  • To confirm the diagnosis in individuals suspected of having HNPCC/Lynch syndrome
  • Positive for MLH1 promoter hypermethylation (CpG island) is consistent with germline (constitutional) inactivation of MLH1. Individuals with germline/constitutional MLH1 promoter hypermethylation are at increased risk for other HNPCC/Lynch syndrome related tumors.
  • Germline/constitutional hypermethylation has bee reported in both familial and sporadic colon cancer.

No methylation or hypermethylation in the MLH1 promoter region (CpG island)

Bisulfite conversion, methylation-specific real-time PCR.

Formalin-fixed, paraffin-embedded tissue block or slides.

Stability

  • Room temperature: indefinitely
Array comparative genomic hybridization (aCGH), immunohistochemistry, denaturing high-performance liquid chromatography, H/E stain, microsatellite instability testing, Lynch Syndrome genetic panel.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Cancer. 2015;121:1395-404. [PMID: 25557234]
  • Gastroenterol Hepatol Bed Bench. 2013; 6: 120–128. [PMID: 24834258]
  • J Mol Diagn. 2010; 12: 498–504. [PMID: 20489114]
  • Cancer. 2009 Feb 15; 115(4): 760–769. [PMID: 19127559]
  • World J Gastroenterol. 2007; 13: 1767–1769. [PMID: 17465465]
  • Gut. 2007; 56: 140–148. [PMID: 16840508]
  • Genetics Home Reference. Available at: https://ghr.nlm.nih.gov/gene/MLH1#
  • GeneReviews® [Internet]. Available at: https://www.ncbi.nlm.nih.gov/books/NBK1211/
  • Giardiello, F. M. Chapter 3; in Hereditary Colorectal Cancer and Polyp Syndromes. Early Diagnosis and Treatment of Cancer Series: Colorectal Cancer, 2011: 21–30. doi:10.1016/b978-1-4160-4686-8.50008-7